Editorial: Probiotics in NASH - More studies are needed

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 211-212

  Ong, J P ^a   Younossi, Z M ^b  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

BODY MASS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DYSBIOSIS; EDITORIAL; HUMAN; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

DIETARY SUPPLEMENTS; FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY; PROBIOTICS;

EID: 84902829151     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12812     Document Type: Editorial

References (7)

1. Chassaing B, Etienne-Mesmin L, Gewirtz AT,. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59: 328-39.
2. Alisi A, Bedogni G, Baviera G, et al,. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276-85.
3. Solga SF, Buckley G, Clark JM, Horska A, Diehl AM,. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008; 42: 1117-9.
4. Vajro P, Mandato C, Licenziati MR, et al,. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-3.
5. Ma Y-Y,. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911.
6. Nobili V, Manco M, Devito R, et al,. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-28.
7. Sanyal AJ, Brunt EM, Kleiner DE, et al,. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-53.